Legend Biotech (LEGN) Notes Payables (2019 - 2022)

Legend Biotech (LEGN) has reported Notes Payables for 4 consecutive years, with $9.7 million the latest figure, recorded in Q1 2022.

• Quarterly Notes Payables rose 100552.92% year-over-year to $9.7 million in Q1 2022, while the trailing twelve-month figure through Mar 2022 was $9.7 million (up 100552.92% YoY) and the FY2021 annual result came in at $7.0 million, up 34.46% from the prior year.
• Notes Payables grew to $9.7 million in Q1 2022 per LEGN's latest filing, from $7.0 million in the prior quarter.
• Over the last five years, Notes Payables for LEGN reached as high as $11.6 million in Q3 2021 and fell as low as $6976.0 in Q2 2020.
• A 4-year average of $6.0 million and a median of $7.0 million in 2021 frame the typical range for Notes Payables.
• Annual changes were most pronounced in 2020 — Notes Payables sank 45.36% — and 2021, when it jumped 157597.82%.
• Year by year, Notes Payables stood at $9.6 million in 2019, then sank by 45.36% to $5.2 million in 2020, then soared by 34.46% to $7.0 million in 2021, then surged by 37.9% to $9.7 million in 2022.
• According to Business Quant data, Notes Payables over the past three periods registered $9.7 million, $7.0 million, and $11.6 million for Q1 2022, Q4 2021, and Q3 2021 respectively.